Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab)

Shinobu Umemura; Yasutomo Sekido; Hitoshi Itoh; R. Yoshiyuki Osamura

doi:10.1267/ahc.35.77

REVIEW

Pathological Evaluation of HER2 Overexpression: For the Treatment of Metastatic Breast Cancers by Humanized Anti-HER2 Monoclonal Antibody (Trastuzumab)

Shinobu Umemura, Yasutomo Sekido, Hitoshi Itoh, R. Yoshiyuki Osamura

著者情報

キーワード: Breast cancer, HER2, Trastuzumab, Immunohistochemistry, FISH

ジャーナルフリー

2002 年 35 巻 2 号 p. 77-81

DOI https://doi.org/10.1267/ahc.35.77

詳細

抄録

For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. This article overviews developments of basic and clinical research for HER2 gene, and introduces general agreement with the evaluation system of HER2 overexpression with several commentaries from the aspect of histochemistry.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）